Drugs / QL1706
QL1706
also known as
Iparomlimab and Tuvonralimab · Tuvonralimab · Iparomlimab · PSB205 · Iparomlimab/Tuvonralimab · Aituo combination antibody · Apalitamab-Tovorizumab · apalolimab · +7 more
Trials 101 · started per year
today
1
4
8
2
7
53
26
20212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07635992 | Jun 2026 → Dec 2028 expected | HIV infectious disease | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07178171 | Nov 2025 → Aug 2027 expected | triple-negative breast carcinoma | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06822985 | Feb 2025 → Aug 2026 overdue | hepatocellular carcinoma | Wan-Guang Zhang | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05171790 | Jan → Dec 2021 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04296994 | Mar 2020 → Dec 2021 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT07863869 | Sep 2026 → May 2029 expected | colorectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07542717 | Apr 2026 → Mar 2028 expected | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07453394 | Apr 2026 → Apr 2027 expected | endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07272590 | Dec 2025 → Jun 2027 expected | metastatic neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07256782 | Oct 2025 → Oct 2026 expected | neoplastic disease or syndrome | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07131345 | Sep 2025 → Oct 2026 expected | malignant mesothelioma | National Cancer Center, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06949761 | Jun 2025 → Sep 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06941766 | Apr 2025 → Apr 2027 expected | trophoblastic neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06766305 | Mar 2025 → Feb 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Xiangdong Cheng | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06809530 | Mar 2025 → Dec 2026 expected | neoplastic meningitis | Guangzhou Medical University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06746961 | Jan 2025 → Jul 2026 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05262413 | Feb 2022 → Jul 2023 | renal cell carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05603039 | Jul 2021 → Dec 2023 | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 268 trials | ||||||
| Phase 2 | NCT07847671 | Oct 2026 → Oct 2029 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07829874 | Sep 2026 → Sep 2028 expected | biliary tract cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07649473 | Aug 2026 → Dec 2028 expected | colon carcinoma, metastasis from malignant tumor of colon | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07841574 | Jun 2026 → Jun 2028 expected | intrahepatic cholangiocarcinoma | Lianghe Lu | Recruiting | No outcome recorded |
| Phase 2 | NCT07595523 | Jun 2026 → Jul 2028 expected | gastric cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07533305 | May 2026 → Jun 2028 expected | esophageal squamous cell carcinoma | The First Affiliated Hospital of Henan University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07601178 | Apr 2026 → Sep 2027 expected | triple-negative breast carcinoma | Jiangsu Cancer Institute & Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07509515 | Apr 2026 → Sep 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07372079 | Apr 2026 → Dec 2028 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07384416 | Apr 2026 → Feb 2029 expected | penile cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07530549 | Apr 2026 → Dec 2027 expected | esophageal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07530445 | Mar 2026 → Apr 2027 expected | — | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07342283 | Feb 2026 → Dec 2027 expected | triple-negative breast carcinoma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07413601 | Feb 2026 → Feb 2029 expected | triple-negative breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07416058 | Jan 2026 → Dec 2027 expected | lung adenocarcinoma | Guangdong Association of Clinical Trials | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07256236 | Jan 2026 → Jun 2028 expected | cervical cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07328009 | Jan 2026 → Jan 2029 expected | hepatocellular carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07315035 | Jan 2026 → Dec 2028 expected | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07327788 | Dec 2025 → Dec 2027 expected | hepatocellular carcinoma, portal vein thrombosis | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07286942 | Dec 2025 → Dec 2027 expected | non-small cell lung carcinoma | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07246317 | Dec 2025 → Dec 2027 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07200947 | Dec 2025 → Dec 2027 expected | non-small cell lung carcinoma | Zhijie Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06787183 | Dec 2025 → Dec 2026 expected | colorectal cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07179900 | Dec 2025 → Dec 2027 expected | hepatocellular carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07389629 | Nov 2025 → Dec 2027 expected | clear cell renal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07286240 | Nov 2025 → Sep 2027 expected | — | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07286253 | Oct 2025 → Sep 2027 expected | — | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07091305 | Oct 2025 → Aug 2027 expected | small cell lung carcinoma | Shanghai Chest Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07141186 | Oct 2025 → Oct 2027 expected | cervical adenocarcinoma, cervical squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07172217 | Oct 2025 → Feb 2027 expected | — | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07205185 | Oct 2025 → Dec 2027 expected | soft tissue sarcoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06939855 | Sep 2025 → May 2027 expected | sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07180160 | Sep 2025 → Sep 2027 expected | female breast carcinoma | Wenjin Yin | Recruiting | No outcome recorded |
| Phase 2 | NCT07175636 | Sep 2025 → Sep 2026 overdue | rectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07119931 | Sep 2025 → Dec 2027 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06967103 | Sep 2025 → May 2027 expected | hormone receptor-positive breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07110064 | Sep 2025 → Aug 2027 expected | — | Du Juan | Recruiting | No outcome recorded |
| Phase 2 | NCT07113964 | Aug 2025 → Mar 2027 expected | Her2-receptor negative breast cancer | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07070700 | Aug 2025 → Aug 2027 expected | intrahepatic cholangiocarcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07083375 | Aug 2025 → Jun 2027 expected | small cell lung carcinoma | Zhijie Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07134413 | Aug 2025 → Oct 2027 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06897046 | Jul 2025 → Feb 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07045805 | Jul 2025 → Jul 2027 expected | gastric cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07049185 | Jul 2025 → Mar 2027 expected | esophageal squamous cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07005583 | Jun 2025 → May 2027 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07009145 | Jun 2025 → Jun 2026 overdue | colorectal cancer | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06892925 | Jun 2025 → Apr 2026 overdue | biliary tract cancer | Eastern Hepatobiliary Surgery Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06917092 | May 2025 → Apr 2027 expected | endometrium adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06911684 | Apr 2025 → Apr 2026 overdue | rectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06801665 | Apr 2025 → Feb 2027 expected | metastasis from malignant tumor of colon | Hua Jiang | Recruiting | No outcome recorded |
| Phase 2 | NCT06884982 | Mar 2025 → Sep 2027 expected | hepatocellular carcinoma | Northern Jiangsu People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06829797 | Mar 2025 → Feb 2028 expected | gastroesophageal adenocarcinoma | Shandong Provincial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06951997 | Mar 2025 → May 2027 expected | pancreatic ductal adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06882447 | Mar 2025 → Dec 2027 expected | cervical carcinoma | Northern Jiangsu People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06750861 | Feb 2025 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06751277 | Feb 2025 → Dec 2026 expected | endometrial cancer | xiang yang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06786026 | Oct 2024 → Sep 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06509971 | Jul 2024 → Feb 2026 overdue | — | West China Second University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06446388 | Jun 2024 → Jun 2026 overdue | neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06313970 | Jun 2024 → Oct 2025 overdue | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06404736 | May 2024 → Nov 2025 overdue | female breast carcinoma, triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06404463 | May 2024 → Nov 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05799820 | Sep 2022 → Mar 2024 | colorectal carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05490719 | Aug 2022 → Sep 2024 | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05329025 | Jun 2022 → Jan 2024 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05309629 | Apr 2022 → Feb 2023 | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05557565 | Dec 2021 → Oct 2022 | cervical cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05179317 | May 2021 → Dec 2022 | cervical cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07636226 | Jul 2026 → Dec 2028 expected | small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05976568 | Sep 2023 → Sep 2027 expected | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05576272 | May 2022 → Dec 2024 | nasopharyngeal carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 38 trials · 1 met primary | ||||||
| Phase 3 | NCT07002346 | Nov 2025 → Jun 2027 expected | ovarian clear cell cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07025239 | Jul 2025 → Jul 2028 expected | colorectal cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06749899 | May 2025 → Dec 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06789796 | Feb 2025 → Mar 2028 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06686576 | Dec 2024 → Dec 2030 expected | colon carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05690945 | Feb 2023 → Jun 2029 expected | lung cancer | Qilu Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05487391 | Dec 2022 → Aug 2027 expected | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05446883 | Sep 2022 → Sep 2024 | cervical cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT07668570 | Jul 2026 → Jul 2029 expected | hepatocellular carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07769853 | Sep 2026 → Jul 2027 expected | rectal cancer | Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07452003 | Jan 2026 → Dec 2028 expected | non-small cell lung carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT06893887 | May 2025 → Dec 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07271602 Background | Jan → Dec 2026 expected | non-small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07070713 Background | Jul 2025 → Feb 2028 expected | colorectal cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Qilu Pharmaceutical Co., Ltd. | Results 2026 ASCO直击：齐鲁制药6项创新研究亮相，多款新药数据发布 qilu-pharma.com ↗
在本次全球肿瘤学术盛会上，齐鲁制药六项创新研究悉数亮相，发布了QLS31905（Claudin18.2/CD3的双特异性T细胞衔接器）、QLC5508（B7H3 ADC）、QL1706（PD-1/CTLA-4双功能组合抗体）、QLF31907（PD-L1/4-BB双抗）及QLS1304（KAT6A/6B小分子抑制剂）等多款新型抗肿瘤药物最新/更新研究数据，聚焦肺癌、消化道肿瘤和妇科肿瘤等领域，多项前沿成果备受行业瞩目。 |
| 2026-03-02 | Qilu Pharmaceutical Co., Ltd. | Results 齐鲁制药齐倍安®一线治疗宫颈癌III期临床研究达到主要研究终点 qilu-pharma.com ↗
近日，齐鲁制药艾帕洛利托沃瑞利单抗（齐倍安®，QL1706）联合化疗±贝伐珠单抗用于一线治疗持续、复发或转移性宫颈癌的III期临床研究（QL1706-301），经独立数据监查委员会（IDMC）评估已达到无进展生存期（PFS）和总生存期（OS）的双阳性。 |
| 2022-07-02 | Qilu Pharmaceutical Co., Ltd. | Results 凤凰新闻丨齐鲁制药PD-1/CTLA-4双抗药物研究成果亮相美国临床肿瘤学会年会，或开创新一代免疫治疗格局 qilu-pharma.com ↗
总体客观缓解率达 24.5%(27/110),疾病控制率为 49.1%(54/110), 中位缓解持续时间达到11.7个月。 |
| 2022-06-03 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Results Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting soundbiologics.com ↗
PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity |
| 2021-04-13 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Results Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting soundbiologics.com ↗
A dose of 5 mg/kg was selected for continued clinical development. |
| 2019-04-10 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Regulatory Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors soundbiologics.com ↗
today announced that U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application and issued authorization to commence a Phase I First-in-Human Clinical Trial of PSB205 for the treatment of patients with relapsed/refractory solid tumors. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Qilu Pharmaceutical Co., Ltd. | 2026 ASCO直击：齐鲁制药6项创新研究亮相，多款新药数据发布 qilu-pharma.com ↗ |
| 2026-03-02 | Qilu Pharmaceutical Co., Ltd. | 齐鲁制药齐倍安®一线治疗宫颈癌III期临床研究达到主要研究终点 qilu-pharma.com ↗ |
| 2022-07-02 | Qilu Pharmaceutical Co., Ltd. | 凤凰新闻丨齐鲁制药PD-1/CTLA-4双抗药物研究成果亮相美国临床肿瘤学会年会，或开创新一代免疫治疗格局 qilu-pharma.com ↗ |
| 2022-06-03 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting soundbiologics.com ↗ |
| 2021-04-13 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Sound Biologics Announces Proof-of-Concept Success at AARC Annual Meeting soundbiologics.com ↗ |
| 2019-04-10 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors soundbiologics.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 105 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL-1706 | “QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103)...” NCT06404736 ↗103“The iparomlimab and tuvonralimab (QL1706) combination is a novel bispecific antibody therapy targeting PD-1 and CTLA-4, designed to enhance anti-tumor immune responses while...” NCT07131345 ↗ “Iparomlimab and Tuvonralimab (QL1706) is a bispecific antibody targeting PD-1 and CTLA-4, enhancing T cell activation and anti-tumor response through synergistic effects.” NCT06911684 ↗ “Ipilimumab-tovorafenib monoclonal antibody injection (Aituo combination antibody, QL1706) contains two engineered monoclonal antibodies targeting PD-1 and CTLA-4.” NCT07635992 ↗ “QL1706 [Iparomlimab and tuvonralimab, a bifunctional anti-programmed death-1/cytotoxic T-lymphocyte antigen-4 antibody]” NCT07542717 ↗ “The specific treatment regimen for QL1706 is as follows: QL1706 (5 mg/kg) via intravenous infusion.” NCT07271602 ↗ “Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)” NCT07119931 ↗ “Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab” NCT07769853 ↗ “QL1706 (also known as PSB205) is an innovative bispecific MabPair™ antibody” NCT07769853 ↗ “QL1706 3mg/kg, IV, D1, Q2W, for a maximum of 2 years.” NCT07863869 ↗ “QL1706 5mg/kg q3w + bevacizumab 7.5mg/kg q3w group” NCT05603039 ↗ |
| Known as | Aituo combination antibody | “Ipilimumab-tovorafenib monoclonal antibody injection (Aituo combination antibody, QL1706) contains two engineered monoclonal antibodies targeting PD-1 and CTLA-4.” NCT07635992 ↗ |
| Known as | Apalitamab-Tovorizumab | “QL1706 (Apalitamab-Tovorizumab; 5 mg/kg, iv, Q3W)” NCT07649473 ↗ |
| Known as | apalolimab | “apalolimab and toripalimab (QL1706)” NCT07286942 ↗ |
| Known as | apolitovorrelizumab | “This study is an open-label, prospective, phase 2, randomized controlled study to evaluate the efficacy and safety of apolitovorrelizumab (QL1706) in combination with platinum...” NCT07413601 ↗ |
| Known as | Avellutolimab | “Avellutolimab (QL1706) combines two engineered monoclonal antibodies-anti-PD-1 and anti-CTLA-4-in a fixed \~2:1 ratio.” NCT07178171 ↗ |
| Known as | Iparomlimab | “Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung...” NCT07286942 ↗5“QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib With or Without Cryoablation for Advanced Biliary Tract Cancer (CASTLE-ZS-04): a Multicenter, Randomized, Phase 2 Study” NCT07829874 ↗ “QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4.” NCT07091305 ↗ “QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody)” NCT06749899 ↗ “QL1706 (iparomlimab/tuvonralimab)+TKI” NCT07328009 ↗ “QL1706 (Iparomlimab/Tuvonralimab)” NCT07315035 ↗ |
| Known as | Iparomlimab and Tuvonralimab | “This clinical trial aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706), a dual-targeting immunotherapy (anti-PD-1/CTLA-4), in patients with...” NCT06941766 ↗6“The iparomlimab and tuvonralimab (QL1706) combination is a novel bispecific antibody therapy targeting PD-1 and CTLA-4, designed to enhance anti-tumor immune responses while...” NCT07131345 ↗ “Iparomlimab and Tuvonralimab (QL1706) is a bispecific antibody targeting PD-1 and CTLA-4, enhancing T cell activation and anti-tumor response through synergistic effects.” NCT06911684 ↗ “QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4.” NCT06789796 ↗ “Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab” NCT07769853 ↗ “Iparomlimab and Tuvonralimab Injection (QL1706)” NCT07327788 ↗ “Iparomlimab and Tuvonralimab (QL1706)” NCT07389629 ↗ |
| Known as | Iparomlimab and Tuvonralimab Injection | “Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen...” NCT07372079 ↗ |
| Known as | Iparomlimab/Tuvonralimab | “Iparomlimab/Tuvonralimab (QL1706)” NCT07595523 ↗1“QL1706 (Iparomlimab/Tuvonralimab)” NCT07649473 ↗ |
| Known as | Ipilimumab-tovorafenib | “Ipilimumab-tovorafenib monoclonal antibody injection (Aituo combination antibody, QL1706) contains two engineered monoclonal antibodies targeting PD-1 and CTLA-4.” NCT07635992 ↗ |
| Known as | lparomlimab | “lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase.” NCT06911684 ↗ |
| Known as | PSB205 | “QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1),...” PMID 37158938 ↗ May 20232“QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1),...” NCT06822985 ↗ “QL1706 (also known as PSB205) is an innovative bispecific MabPair™ antibody” NCT07769853 ↗ |
| Known as | QL1706 Injection | “QL1706 Injection (QL1706) is a combination antibody developed by Qilu Pharmaceutical Co., Ltd.” NCT06949761 ↗ |
| Known as | toripalimab | “apalolimab and toripalimab (QL1706)” NCT07286942 ↗ |
| Known as | Tuvonralimab | “Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung...” NCT07286942 ↗6“QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and...” NCT07601178 ↗ “QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib With or Without Cryoablation for Advanced Biliary Tract Cancer (CASTLE-ZS-04): a Multicenter, Randomized, Phase 2 Study” NCT07829874 ↗ “QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4.” NCT07091305 ↗ “QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody)” NCT06749899 ↗ “QL1706 (iparomlimab/tuvonralimab)+TKI” NCT07328009 ↗ “QL1706 (Iparomlimab/Tuvonralimab)” NCT07315035 ↗ |
| Action | Inhibit | “QL1706, a bifunctional PD-1/CTLA-4 dual blocker” PMID 41045933 ↗ Oct 2025 |
| Modality | Monoclonal antibody | “QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies” PMID 37158938 ↗ May 2023 |
| Route | Intravenous | “via IV infusion” NCT04296994 ↗ |